The first two authors contributed equally to this work Apicidin is a fungal metabolite shown to exhibit anti-proliferative, anti-invasive, and anti-inflammatory properties by the inhibition of histone deacetylase (HDAC). However, the effects of apicidin on the maturation and immunostimulatory function of dendritic cells (DCs) remain unknown. In this study, we investigated whether apicidin modulates surface molecule expression, cytokine production, endocytosis capacity, and underlying signaling pathways in murine bone marrow-derived DCs. We observed that apicidin significantly attenuated surface molecule expression in LPS-stimulated DCs, suppressed production of interleukin (lL)-12 and proinflammatory cytokines (IL-6 and TNF-a) by DCs, and reduced IFN-y production by T cells. The apicidin-treated DCs were found to be highly efficient in antigen capture via mannose receptor-mediated endocytosis. Apicidin also inhibited LPS-induced MAPK activation and NF-KB nuclear translocation in DCs. Moreover, the apicidin-treated DCs were incapable of inducing Thl responses and normal cell-mediated immune responses. These novel findings not only provide new insights into the immunopharmacological role of apicidin in terms of its effects on DCs, but also broaden current perspectives of the immunopharmacological functions of apicidin, and have implications for the development of therapeutic adjuvants for the treatment of DC-related acute and chronic diseases.
condensation and transcriptional repression (1). In humans, 18 HDACs have been identified and subdivided into three individual classes based on structural and functional similarities. The class I isoforms (HDACs 1,2,3 and 8) and class II (HDACs 4,5,6,7,9, 10 and 11) are Zn-dependant enzymes, whereas class III HDACs (sirtulinl-7) are NAD+dependant (2) . HDAC inhibitors are grouped into five categories: 1) hydroxamic acids like trichostatin A (TSA), suberolyanilide hydoxamic acid (SAHA), belinostat, NVP-LAQ824, panobinostat and ITF2357; 2) short-chain fatty acids like butyric acid (BA) and valpronic acid (VPA); 3) electrophilic ketones like trifluorometyl ketones; 4) aminobenzoamides like MS-275, CI-994 and MGCDOI03; 5) natural cyclic peptides like romidepsin and apicidin. Apicidin [cyclo(N-O-metyl-L-tryptophanyl-L-iso leuc i ny 1-D-pipecoliny 1-L-2-am ino-8oxodecanoyl)] is a novel cyclic tetrapeptide with a potent broad spectrum of antiprotozoal activity against Apicomplexan parasites (3) . Furthermore, it has been shown to diminish the activity of HDAC partially purified from Eimeria tene/la as well as to enhance hyperacetylation of histone in Plasmodium falciparum (3) . Its structure is related to trapoxin, a well-known potent HDAC inhibitor. Apicidin has been demonstrated to have antiproliferative activity and toxicity in some cancer cell lines (4) . These potent chemopreventative activities of apicidin may be attributed to the inhibition of specific signal transduction pathways critical to tumor cell growth, including PI3 kinase, protein kinase C and NF-KB (5) . In addition, apicidin has been demonstrated to inhibit the proliferation of tumor cells though increasing levels ofp21WAF/Cipl (4) . Recently, it has been shown that apicidin inhibits tumor invasion through the inhibition of matrix metalloproteinase-2 in a human melanoma cancer cell line (6) . In addition to their anticancer activities, several HDAC inhibitors have been shown effective in immune disease models. Specifically, TSA inhibited adjuvant-induced rheumatoid arthritis in rats (7) , and was capable of suppressing clinical symptoms in a murine model of multiple sclerosis (8) . In addition, SAHA has been shown to inhibit graft-versushost disease in a murine model of bone marrow transplantation (9) .
The biology of bone marrow-derived dendritic cells (BMDCs) and their potential for clinical use in cellular therapies for chronic infectious diseases and tumors are the focus of considerable research interest (10) . BMDCs are professional antigen presenting cells (APCs), playing key roles in the immune sentinels as initiators of T cell responses against microbial pathogens and tumors, and are involved in inflammatory responses (11) . Under steady state conditions, DCs are present in peripheral tissues in an immature state and exert a guard function that protects against incoming antigens (12) . Immature DCs do not enhance primary immune responses, as they do not express the requisite costimulatory molecules, nor do they express antigenic peptides as stable complexes with major antigen peptide presenting histocompatibility complex (MHC) molecules. During pathogen invasion or after exposure to inflammatory cytokines, DCs undergo phenotypic changes associated with functional maturation (10) . The maturing DCs then migrate to lymphoid organs, where they stimulate naive T cells through the signals of both MHC molecules presenting antigen peptides and costimulatory molecules, leading to subsequent initiation of adaptive immune responses (13) . The maturation of DCs is associated with a reduction or the absence of antigen uptake, high levels of MHC class II and accessory molecule expression, and the production of IL-12 upon stimulation (10) . Recently, other HDAC inhibitors have been reported to suppress the differentiation and function of DCs (14) (15) . However, the cellular targets of apicidin in the immune system are poorly understood, especially those involved in affecting DCs, leaving the question of its global function in the maturation and immunoregulatory activities of DCs unanswered. In this study, we analyzed the effects of a nontoxic concentration of apicidin on maturation and functional properties of murine BMDCs. Our results suggest that apicidinis a potent inhibitor of myeloid DC maturation. Apicidin treatment also inhibited the LPS-induced activation of ERKl/2, JNK, p38, and the nuclear translocation of the NF-KB p65 subunits in the DCs. These findings provide new insights into the immunopharmacology of apicidin. Moreover, this readily available drug may constitute a simple, inexpensive, and highly effective means for the manipulation of the immunostimulatory capacity of DCs. Due to the critical role of these professional APC on the initiation and regulation of immune responses and the availability of apicidin, our findings may have important implications for the manipulation of DC functions for potential therapeutic applications.
MATERIALS AND METHODS

Animals
Male 8-12-week-old C57BLl6 (H-2Kb and I-N) and BALB/c (H-2Kd and I-Ad) mice were purchased from the Korean Institute of Chemistry Technology (Daejeon, Korea). They were housed in a specific pathogen-free environment within our animal facility for at least 1 week before use.
Reagents and Abs
Apicidin and TSA were purchased from Biomol international (Plymouth Meeting, PA, USA). Recombinant mouse (rm) granulocyte-macrophagecolony stimulating factor (GM-CSF) and rm interleukin (IL)-4 were purchased from R&D Systems (Minneapolis, MN, USA). Dextran-FITC (molecular mass, 40,000) and LPS (from Escherichia coli 055:B5) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Cytokine ELISA kits for murine IL-12 p70, IL-6, TNF-u, IL-4 and IFN-y were purchased from R&D Systems (Minneapolis, MN, USA). FITC-conjugated or PE-conjugated mAbs used to detect the expression of CD 11c (HL3), CD80 (16-IOA 1), CD86 (GLl), anti-MHC class I, and MHC class II or the intracellular expression of IL-12 p40/p70 (CI5.6), and IL-IO (JESS-16E3) by flow cytometry, as wel1 as isotype-matched control mAbs, biotinylated anti-CD 11c (N418) mAb, Cytofix/Cytoperm kit and FITC-annexin V in combination with a propidium iodine kit were purchased from BD Pharmingen (Franklin Lakes, NJ, USA). To detect protein levels, anti-phospho-ERK (1: 1,000), anti-phospho-JNK (1:500), anti-phospho-p38 (1: 1,000), anti-ERK (1:2,000), anti-p65 (1:1 ,000), and anti-Topo isomerase (TopoI)( 1:1,000) antibodies were from Santa Cruz biotechnology, (Santa Cruz, CA, USA). Beadconjugated anti-CDllc mAb and paramagnetic columns (LS columns) were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).
Generation and culture ofDC
DCs were generated from murine bone marrow monocytes according to the procedure of Inaba et al. (16) with minor modification. Briefly, bone marrow was flushed from the tibiae and femurs of6-8-week-old male C57BLl6 mice and depleted of red blood cel1s with Red Blood cel1
Lysing buffer (Sigma-Aldrich, St. Louis, MO). The cel1s were plated in 6-wel1culture plates (1 10 6 cells/rnl.; 2 mLi wel1) in RPMl supplemented with 10% heat-inactivated FBS, 100 U/mL penicilline, 100 mg/mL stereptomycin, 20 ng/mL rmGM-CSF and 20 ng/mL rmIL-4 at 37°C in a humidified 5% CO 2 atmosphere. On day 3 and 5 of the culture, floating cel1s were gently removed and fresh medium was added. On day 6 of the culture, non-adherent cel1s and loosely adherent proliferating DC aggregates were harvested for analysis or stimulation. On day 7, 80% or more of the non-adherent cel1s expressed CD 11c. In certain experiments, to obtain highly purified populations for subsequent analyses, the DC were labeled with beadconjugated anti-CD II c mAb (Miltenyi Biotec, Bergisch Gladbach, Germany) fol1owed by positive selection through paramagnetic columns (LS columns; Miltenyi Biotec) according to the manufacturer's instructions. The purity of the selected cel1 fraction was >95%.
Stimulation ofDC by apicidin
Apicidin were dissolved in DMSO, or DMSO alone (0.01% v/v) was added to cultures of isolated DC in six-wel1 plates (10 6 cel1s/mL; 2 mLlwel1). DMSO (0.1%) alone was used as a control due to the lack of no cytotoxicity in DCs. For the analysis of apoptosis, DCs were pre-treated with or without apicidin (0 -0.2 ug/ml.) for 2 h, then cel1s were incubated with LPS (200 ng/mL) for 24 h. Additional1y, apoptosis was analyzed over time by staining phosphatidylserine translocation with FITCannexin V in combination with a propidium iodine kit according to the manufacturer's instructions.
Flow cytometric analysis
On day 6, BMDC were harvested, washed with phosphate buffered saline (PBS) and resuspended in fluorescence activated cel1 sorter (FACS) washing buffer (2% fetal bovine serum and 0.1% sodium azide in PBS). Cel1s were first blocked with 10% (v/v) normal goat serum for 15 min at 4°C and stained with phycoerythrin (PE)-conjugated anti-CD80, anti-CD86, anti-MHC class I, and MHC class II with fluorescein isothiocyanate (FITC)-conjugated anti-CDIlc for 30 min at 4°C. The stained cel1s were analyzed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA).
Quantitation ofAg uptake
Endocytosis was quantitated, as described by Lutz et al. (17) . In brief, 2 x 10 5 cel1s were equilibrated at 37 or 4°C for 45 min and then pulsed with fluoresceinconjugated dextran at a concentration of 1 mg/mL. Cold staining buffer was added to stop the reaction. The cel1s were washed three times and stained with PE-conjugated anti-CDllc Abs, and then analyzed by FACSCalibur.
Non-specific binding of dextran to DC, determined by incubation of DC with FITC-conjugated dextran at 4°C, was subtracted. The medium used in the culture, to stimulate DC with apicidin, was supplemented with GM-CSF, because the ability of DC to capture Ag is lost if DC are cultured without GM-CSF (18) .
Cytokines assay
Cells were first blocked with 10% (v/v) normal goat serum for 15 min at 4°C and then stained with FITCconjugated CDllc+ antibody for 30 min at 4°C. Cells stained with the appropriate isotype-matched Ig were used as negative controls. The cells were fixed and permeated with the Cytofix/Cytoperm kit according to the manufacturer's instructions. Intracellular IL-12 p40/p70 and IL-IO were stained with fluorescein Rphycoerythrin (PE)-conjugated antibodies in a permeation buffer. The cells were analyzed on a FACSCalibur flow cytometer using the CellQuest program. Furthermore, murine IL-12 p70, IL-6, TNF-a, IL-4, and IFN-y from DC were measured using an ELISA kit according to the manufacturer's instructions.
Mixed lymphocyte reaction
Responder T cells, which participate in allogeneic Tcell reactions, were isolated from the spleen of BALB/c mice with a MACS column. Staining with fluorescein isothiocyanate (FITC)-conjugated anti-CD3 antibodies revealed that they consisted mainly of CD3+ cells (> 95%). The lymphocyte population (95% ofCD3+ cells) was then washed twice in PBS and labeled with CFSE, as previously described (19) . The cells were resuspended in 5 /lM CFSE in phosphate-buffered saline (PBS). After being shaken for 8 min at room temperature, the cells were washed once in pure fetal bovine serum (FBS) and twice in PBS with 10% FBS. DC (1 x 10 4 ) or DC exposed to apicidin (0.1 ug/rnl.) or LPS (200 ng/mL) for 24 h were cocultured with I x 10 5 allogeneic CFSE-Iabeled T lymphocytes in 96-well, U-bottom plates (Nunc, Roskilde, Denmark). A negative control (CD3+ lymphocytes alone) and a positive control (CD3+ lymphocytes in 5 ug of Concanavalin A) were created for each experiment. After 4 days, the cells were harvested and washed in PBS. CFSE dilution optically gated lymphocytes were assessed by flow cytometry.
Nuclear and cytoplasmic extracts and Western blot
DCs were washed twice with Tris-buffered saline and lysed by the addition of ice-cold lysis buffer, containing 0.5% Triton X-100, 50 mM Tris (pH 8.0), 150 mM NaCI, 5 mM EDTA, 5 mMNaF, ImM Na jV0 4 , lO'/lg/mL aprotinin and pepstatin A, and 5 ug/ml. leupeptin. Lysates were incubated on ice for 20 min and microcentrifuged for 30 min at 12,000 x g at 4°C to remove nuclei. Proteins were separated on 10% SDS-polyacrylamide gels and transferred to PVDF membranes. Membranes were blocked with 5% non-fat dried milk in T-PBS (0.2% Tween 20 in PBS) and incubated with a primary antibody against anti-phospho-ERKl/2 (1: I,000), antiphospho-JNK (1:500) or anti-phospho-p38 (1:1,000); an anti-EKR2 (1:2,000) antibody was used as a control for equal loading. Membranes were subsequently washed and incubated for 1 h with horseradish peroxidase-conjugated secondary antibody. Immunolabeling was detected using an ECL detection system (Millipore Corporation, Billerica, MA, USA). DC nuclear extracts were prepared using NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL, USA, according to the manufacturer's instructions. NF-KB p65 subunits in the nuclear extracts were determined by Western blot analysis with anti-NF-KB p65 subunitAb (1:2,000). Anti-Topol (1: 1,000) antibody was used as a control for equal loading.
HDAC activity
DCs were pre-treated with apicidin (0.1 ug/rnl.) and TSA (1 /lM) for 2 h, then cells were incubated with LPS (200 ng/mL) for 24 h. HDAC activity was measured by using a HDAC Colorimetric Assay Kit (MBL international, Woburn, MA, USA).
ChIP assay
ChIP assays were carried out using a ChIP Assay Kit (Upstate Biotechnology Inc., CA, USA), according to a modification of the manufacturerl.l instructions. After stimulation, protein-DNA complexes were crosslinked by formaldehyde (1% final concentration). Cells were resuspended in 200 III of SDS lysis buffer [50 mM Tris (pH 8.1), 1% SDS, 5 mM EDTA, and complete proteinase inhibitor mixture] and subjected to five cycles of sonication on ice with 10-s pulses. Sonicated samples were centrifuged to spin down cell debris, and the soluble chromatin solution was immunoprecipitated using Abs specific for Rel-A (Santa Cruz biotechnology, Santa Cruz, CA, USA). Protein-bound immunoprecipitated DNA was washed with LiCI wash buffer and 10 mM Tris and I mM EDTA (pH 8.0), and immune complexes were eluted by adding elution buffer (I % SDS and 0.1 M NaHC0 3 ) , followed by incubation for 4 h at 65°C in 200 mM NaCI and 1% SDS to reverse cross-links and incubation for I h at 45°C with 70 ug/ml proteinase K (Sigma-Aldrich, St. Louis, MO). DNA was extracted with phenol/chloroform, precipitated with ethanol/0.3 M NaHCOOH/20 ug glycogen, and resuspended in 100 III of nuclease-free water. Real time-PCR was performed with 8 /ll of DNA sample for quantification. The amount of DNA in each ChIP sample was normalized to the input. All real-time PCR data were presented as the fold induction from control samples . The sequences of IL-1 2 p40 promoter primer including Rel-A binding region are as follows: forward primer 5'-TCCTTCCTTTTTCCACACCC-3' and reverse primer 5'-TGTCAAAACATTCTGGGGGA-3'.
Statistical Analys is
Experim ents were repeated at least three times with consistent results. Unless otherwise stated, data are expressed as the mean ± SEM. ANOVA was used to compare experimental groups to control values , and Tukey's Multiple Comparison test was used to compare between multip le groups. P values < 0.05 were considered statistically significant.
RESULTS
Apicidin inhibits the LPS-induced HDAC activity in BMDCs
In the first series of experiments , we assessed whether the histone deacetylase inhibitor apicidin influences the maturation of DCs. Here, BMDCs were cultured for six days in RPMI supplemented with 20 ng/mL of GM-CSF and 20 ng/mL of IL-4. To exclude the possibility that any impairment of DC function observed followed by treatment with apicidin is due to a reduction of DC numbers through apoptosis , we tested apoptotic sensitivity of DCs to staining until reaching a concentration of 0.1 ug/ml, apicidin (Fig . 1) . The level of in vivo histone acetylation is regulated by the balance between HAT and HDAC . To investigate the sensitivity of immature DC response to apicidin, we first analyzed HDAC activity following LPS stimulation of immature DCs. Here, we found that LPS treatment stimulated HDAC activity in a time -depen dent manner ( Fig .  2A) . Next , to investigate whether apicidin has effects on LPS-induced HDAC activity in BMDCs, cells were pre-incubated with 0.1 ug/ml, apicid in, or with 1~M TSA for 2 h prior to 200 ng/mL LPS stimu lation for 24 h. TSA is very effective in HDAC inhibition at nanomolar concentration in vitro (2) . Thus, we used TSA, which is one of the most representative HDAC inhibitors, as positive control. As shown in Fig. 2B , LPS-induced HDAC activity was strongly suppressed in apicidin -and TSAtreated DCs, indicating that LPS stimulates HDAC activity in murine BMDCs, and that apicid in may act as a potent inhibitor of this HDAC activity.
Apicidin inhibits the LPS-induced maturation of BMDCs
To investigate the role of different concentrations of apicidin in DC maturation, we measured the expression levels of co-stimulatory molecules (CD80 , CD86, MHC class I, and MHC class II) in DCs pre-treated with various concentrations of apicidin for 2 h, and further incubated with or without LPS (200 ng/mL) for 24 h. As shown in Fig. 3A and Table I , apicidin did not affect the expression of CD80, CD86 , MHC class I, and MHC class II on CD 11 c" cells on day seven; however, after stimulation of cells with LPS for 24 h on day six, the co-stimulatory molecule expression was strongly enhanced ( Fig . 3B and Table I ). Apicidin-treated DCs displayed significantly reduced the levels of these co-stimulatory niolecules compared with untreated cells (Fig. 3B and Table I ), indicating that apicidin-treated DCs were at least partially resistant to phenotypic maturation.
Apicidin reduces the secretion of 1L-12 and other proinfiammatory cytokines, but does not detect ILi Osecretion during LPS-induced maturation
A major attribute of mature DC is the synthesis and release of cytokines with important modulatory functions involved in inflammation and T cell differentiation. A variety of inflammatory cytokines, such as IL-I~, IL-6, IL-12, and TNF-a, were produced in DCs. IL-12 production also serves as an important marker for DC maturation and can be used as a method of selecting Th l-dominant adjuvant. Secretion of bioactive IL-12 p70 requires the coordinated expression of two subunits, p35 and p40, which are encoded by two separate genes and are regulated independently (20) . Thus, we examined whether apicidin regulates cytokine production following LPS-induced DC maturation. Intracellular staining of FITC-Iabeled anti-CD 11 c" DCs with PE-Iabeled anti-IL-12 p40/p70 or anti-IL-IO mAbs demonstrated that LPS-stimulated DCs, in the presence of various concentrations of apicidin, expressed lower amounts of1L-12 p40/p70 compared with LPS-stimulated DC in the absence of apicidin; IL-IO was not detectable (Fig. 4A ). When cell supernatants were analyzed by ELISA, apicidin alleviated the effect of LPS stimulation of DCs on IL-12 p70 production ( Fig. 4B ). In addition, apicidin inhibited the release of proinflammatory cytokines, including IL-6 and TNF-a, from LPS-stimulated DCs (Fig. 4C) . These data indicate that following exposure to apicidin, LPS-stimulated DCs displayed an impaired ability to produce high amounts of IL-12 p70, suggesting that apicidin suppresses the maturation of LPS-stimulated DCs.
Apicidin inhibits LPS-induced IL-I2 p40 transcriptionfactor recruitment in BMDCs
It has been previously reported that a prerequisite to efficient IL-12 p40 transcription is chromatin remodeling by ReI-A, also referred to as p65 subunit Figure 3A of NF-KB , binding within the promoter (21) . To find the transcription factor target of apicidininduced IL-12 p40 inhibition, we exami ned ReI-A recruitment to the IL-12 p40 promoter using ChIP assays. LPS increased the associati on of Rel-A to the IL-12 p40 promoter in BMDCs, an effect that was inhibited by either apicidin or TSA (Fig. 5) . These data indicate that apicidin impaired the ability to produce high amounts of IL-12 p70 by suppression of the recruitment of Rel-A transcription factor to the IL-12 p40 promoter, which is clearly relevant to the regulation of LPS-induced DC maturation.
Apicidin induces the immature state of Des with high endocytic capacity
The surface molecule expression profile and . . reduction in IL-12 p70 production indicated that exposure to apicidin significantly abrogated the phenotypic and functional maturation of in vitro generated DCs. However, these results did not exclude the possibility that apicidin may enhance a general block of the physiological functions of DCs. For these reasons , we assessed the ability ofapicidintreated DCs to capture antigens based on uptake of FITC-conjugated dextran. Briefly, we exposed the DCs to LPS in the presence or absence of apicidin , and then added dextran-FITC to the culture media. The percentage of double-positive cells (CD II c' and dextran-FITC) in LPS-stimulated DCs in the absence ofapicidin ( Fig. 6A-b ) was down-regulated compared to that in DCs incubated without LPS ( Fig.  6A-a) . However, the percentage of double positive LPS-stimulated DCs in the presence of apicidin was significantly enhanced compared to that observed in LPS-stimulated DCs (Fig. 6A-d and f) . Identical experiments were also performed at 4°C, and these results indicated that the uptake of dextran-FITC by DCs was inhibited at low temperatures (Fig. 6B ). Taken together, these data indicate that apicidin induced the immature state of DCs.
Apicidin decreases the phosphorylation of MAPKs and the nuclear translocation of transcription factors in BMDCs
Since evidence suggests that the activation ofNF-KB is an important event underlying DC maturation (18) and that LPS stimulation has been shown to activate MAPK and NF-KB signaling pathways in DCs (22) , we sought to determine whether apicidin is involved in regulating MAPKs and NF-KB activation in LPS-stimulated DCs. First, to investigate the effects of apicidin on the activation of ERKl/2, JNK, and p38 in LPS-stimulated DCs, cells were incubated with various concentrations of apicidin for 2 hours prior to LPS stimulation. As shown in Fig.  7A , apicidin abrogated LPS-induced up-regulation of phosphorylation in ERKl/2, JNK, and p38 in a dose-dependent manner. Next, to determine whether apicidin decreases LPS-induced activation ofNF-KB, nuclear translocation of the NF-KB p65 subunit was evaluated by Western blot analysis. Here, we found that LPS induced the translocation of the NF-KB p65 subunit into the nucleus, and that pretreatment with apicidin significantly attenuated the LPS-induced NF-KB p65 nuclear translocation (Fig. 7B) . These data indicate that apicidin inhibits the activation of MAPKs and NF-KB, which is clearly relevant to the regulation of LPS-induced DC maturation.
Apicidin inhibits the capacity ofDCs to induce Thl responses
CFSE allows for the accurate tracking of the number of divisions that a given cell has undergone, either in vitro or following transfer in vivo (19) . In order to determine whether apicidin exerts detectable effects on allogeneic T cell stimulation, we subjected the DCs to 24 hours of stimulation with apicidin, and measured the rate of proliferation. As shown in Fig. 8A , the rate of proliferation of allogeneic T cells was enhanced when co-cultured with LPStreated DCs (Fig. 8A-f , Table II) , and appeared to be faster than those co-cultured with untreated DCs (Fig. 8A-b , Table II ). However, apicidin attenuated the rate of proliferation responses in the allogeneic T cells elicited following co-culture with the LPS-stimulated DCs (Fig. 8A-g and h, Table  II ), indicating that the maturation induced by LPS stimulation profoundly promoted the allostimulatory capacity of the untreated DCs, whereas exposure to apicidin significantly abrogated their allostimulatory capacity. Considering the inhibitory effects of apicidin on the IL-12 production as a Th1-inducing cytokine in DCs, we next looked to characterize the quality of the primary T-cell response from interaction with DCs that had matured in the presence ofapicidin. Naive allogeneic T cells primed with mature DCs were observed to differentiate into Thl lymphocytes, as they generated high levels of IFN-y and low levels of IL-4 ( Fig. 8B ). By way of contrast, T cells primed with DCs that had matured in the presence of apicidin displayed reduced levels of IFN-y production. These results show that the majority of apicidin's effects on T cell differentiating properties of DC are a consequence of the inhibition ofIL-12 production.
DISCUSSION
This, to the best of our knowledge, is the first report of the effects of natural cyclic peptide-based HDAC inhibiter on the phenotypic and functional maturation of BMDCs. This is also the first study in which natural cyclic peptide-based HDAC inhibiter-exposed DCs have been analyzed with regard to their capacity to sensitize recipients for cell-mediated immune responses. We performed further experiments with apicidin to evaluate the underlying mechanism of natural cyclic peptidebased HDAC inhibitor's function in DC maturation for several reasons. 1) hydroxamic acid-based HDAC inhibitors such as TSA and SAHA inhibited DC maturation (14) . In addition, short-chain fatty acid-based HDAC inhibitor such as VPA and amibobenzamides-based HDAC inhibitor such as MS-275 inhibited the differentiation and function of human monocyte-derived DC (15) . To date, however, there is no proven cyclic peptide-based HDAC inhibitor such as apicidin that can affect the maturation and immunological responses of DCs. 2) Most HDAC inhibitors decrease all class I and II HDAC isoforms without isoform specificity (2) . However, VPA and some recently developed HDAC inhibitors, such as MS-275 and apicidin, show isoform specific, mostly class I, inhibition (2) . 3) Although VPA (millimolar range) and MS-275 (micromolar range) are selectively inhibited class I HDAC, the concentration of apicidin to inhibit class I HDAC is lower than that ofVPA or MS-275 (2). 4) Although transient histone H4 acetylation by TSA (23) in human keratinocytes, the histone hyperacetylation in HeLa cells by apicidin was persistent up to 48 hours (4) .
DCs are also considered as playing important roles in deciding the establishment of immunity and transplantation tolerance (24) . In this study, we conducted a series of functional assays in order to ascertain the phenotype and function of apicidintreated DCs. Our findings indicate that the effects of apicidin are principally involved in the suppression of MAPKs and NF-KB activation. To confirm that the observed effects of apicidin could be attributed to DCs and not to contaminating cells persisting in the BMDC cultures, the DCs were purified (> 95%) prior to analysis in each of the conducted assays. Our findings suggest that apicidin may be a potent inhibitor of LPS-induced DC maturation, as apicidin inhibited DC maturation in a dose-dependent manner. These findings provide new insights into the immunopharmacology of apicidin in DC-related immune responses. The profound suppressive effects of apicidin on DC maturation could be attributed to a non-specific inhibitory effect, therefore, we also assessed the ability of apicidin-treated DCs to internalize FITC-dextran via mannose receptormediated endocytosis, a defining characteristic of mature, as opposed to immature, DCs (25) . The endocytic capacities of the apicidin-treated DCs were found to be profoundly elevated compared to controls, thereby suggesting that apicidin inhibits both the phenotypic and functional maturation of DCs.
It is well accepted that NF-KB signaling pathways play important roles in the maturation of DCs (18) . While there are several important molecules, such as NF-KB, IKB, IKB kinase, within NF-KB signaling pathway, NF-KB is considered the key molecule in the pathway, and has been described as a major culprit and a therapeutic target in mature DC-related diseases. In addition to NF-KB, MAPKs have received increasing attention as target molecules for mature DC-related therapy. It has been reported that activation of MAPKs may cause the induction of phase II detoxifying enzymes, and the inhibition of MAPK pathways may inhibit AP-l-and/or NF-KBmediated gene expression (26) . MAPK pathways consist of a three-tiered kinase core, where a MAP3 K activates a MAP2K that activates a MAPK such as ERK, JNK, and p38), resulting in the activation of NF-KB, cell growth, and cell survival (27) . In this study, we conducted an evaluation of MAPKs and NF-KB signaling pathways in order to characterize the mechanism underlying the inhibitory effects of apicidin on LPS-induced DC maturation. Apicidin exerted a detectable suppressive effect on the phenotypic and functional maturation of murine BMDCs through the inhibition of ERKl/2, JNK, and p38 MAPK activation. We also found that the NF-KB signaling pathway may be involved in the DC maturation-inhibitory effects of apicidin.
Recently, collected evidence suggests that cytokine production in DCs is dependent on either the particular subset ofDC, or on the stimuli received by the DC (28) . IL-12, in particular, exerts multiple immunoregulatory functions, inducing the activation of the Thl subset, which performs a pivotal role in the induction of inflammation (29) . A growing body of evidence suggests that development toward Th 1 cells is primarily regulated by DC-derived cytokines, including IL-12 and IFN-y (30) . The results obtained in this report indicate that apicidin caused CD 11 c" DCs to generate IL-12 in the presence of LPS, and also confirm that apicidin exerts inhibitory effects on the expression of intracellular IL-12 p40/p70 and IL-12 p70. Additionally, this study indicates that LPS-stimulated Cl.rl lc" DCs skew naive T cells toward development into IFN-y-producing T cells. Apicidin significantly impaired the capacity of these cells to proliferate and initiate Th 1 responses. Naive T cells stimulated with apicidin-treated DCs generated lower levels of IFN-y, but did not exhibit significantly altered abilities to generate IL-4, indicating that apicidin is a potent DC maturation inhibitor. Since Thl cells exert functionally immunogenic or protective effects against invading pathogens, the inhibition of DC-mediated Thl polarization may constitute an apicidin-associated immunosuppressive mechanism. However, the inhibition of Th l development exerts negative regulatory roles on a wide variety of immune cells (20) . Consequently, apicidin-mediated inhibition of IL-12 generation in LPS-stimulated CD 11c' DCs may also contribute to the induction of an immunosuppressive state.
In conclusion, we have characterized a variety of effects exerted by apicidin on BMDCs. Apicidin was demonstrated to inhibit phenotypic maturation and modulate cytokine production in these DCs, resulting in a significant inhibition of Th l development. Moreover, our data demonstrate that apicidin attenuated expression of LPS-induced costimulatory molecules, MHC class types, and IFN-y. These findings illustrate the immunopharmacological functions of apicidin, as exposure to this readily available drug may constitute a non-toxic and highly effective means for the modulation of DC immunoregulatory capacity.
